Cargando…
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599832/ https://www.ncbi.nlm.nih.gov/pubmed/26451848 http://dx.doi.org/10.1371/journal.pone.0140623 |
| _version_ | 1782394326950608896 |
|---|---|
| author | Amin, Janaki Boyd, Mark A. Kumarasamy, Nagalingeswaran Moore, Cecilia L. Losso, Marcello H. Nwizu, Chidi A. Mohapi, Lerato Kerr, Stephen J. Sohn, Annette H. Teppler, Hedy Renjifo, Boris Molina, Jean-Michel Emery, Sean Cooper, David A. |
| author_facet | Amin, Janaki Boyd, Mark A. Kumarasamy, Nagalingeswaran Moore, Cecilia L. Losso, Marcello H. Nwizu, Chidi A. Mohapi, Lerato Kerr, Stephen J. Sohn, Annette H. Teppler, Hedy Renjifo, Boris Molina, Jean-Michel Emery, Sean Cooper, David A. |
| author_sort | Amin, Janaki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4599832 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Public Library of Science |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-45998322015-10-20 Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection Amin, Janaki Boyd, Mark A. Kumarasamy, Nagalingeswaran Moore, Cecilia L. Losso, Marcello H. Nwizu, Chidi A. Mohapi, Lerato Kerr, Stephen J. Sohn, Annette H. Teppler, Hedy Renjifo, Boris Molina, Jean-Michel Emery, Sean Cooper, David A. PLoS One Correction Public Library of Science 2015-10-09 /pmc/articles/PMC4599832/ /pubmed/26451848 http://dx.doi.org/10.1371/journal.pone.0140623 Text en © 2015 Amin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
| spellingShingle | Correction Amin, Janaki Boyd, Mark A. Kumarasamy, Nagalingeswaran Moore, Cecilia L. Losso, Marcello H. Nwizu, Chidi A. Mohapi, Lerato Kerr, Stephen J. Sohn, Annette H. Teppler, Hedy Renjifo, Boris Molina, Jean-Michel Emery, Sean Cooper, David A. Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection |
| title | Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection |
| title_full | Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection |
| title_fullStr | Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection |
| title_full_unstemmed | Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection |
| title_short | Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection |
| title_sort | correction: raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of hiv-1 infection |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599832/ https://www.ncbi.nlm.nih.gov/pubmed/26451848 http://dx.doi.org/10.1371/journal.pone.0140623 |
| work_keys_str_mv | AT aminjanaki correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT boydmarka correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT kumarasamynagalingeswaran correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT moorececilial correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT lossomarcelloh correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT nwizuchidia correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT mohapilerato correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT kerrstephenj correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT sohnannetteh correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT tepplerhedy correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT renjifoboris correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT molinajeanmichel correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT emerysean correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT cooperdavida correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection AT correctionraltegravirnoninferiortonucleosidebasedregimensinsecondlinetherapywithlopinavirritonavirover96weeksarandomisedopenlabelstudyforthetreatmentofhiv1infection |